Author

Gail T. McDonald

Observed names: Gail McDonald, Gail T McDonald

Observed institutions: Queen's University, Canadian Cancer Trials Group

OpenAlex ID: A5015632543

Activated Macrophages Inhibit Human Cytotrophoblast Invasiveness In Vitro1

2005 · Stephen J. Renaud, Lynne-Marie Postovit, et al. · Biology of Reproduction · 151

Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression

2010 · Gail T. McDonald, Richard Sullivan, et al. · Experimental Cell Research · 40

Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer

2020 · Srikala S. Sridhar, Normand Blais, et al. · JAMA Oncology · 37

Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome

2015 · Jose G. Monzon, Annette E. Hay, et al. · European Journal of Cancer · 24

Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN ‐003/ MYX .1 single arm phase II trial

2021 · Christopher P. Venner, Richard LeBlanc, et al. · American Journal of Hematology · 13

Cctg BL12: Randomized phase II trial comparing nab-paclitaxel (Nab-P) to paclitaxel (P) in patients (pts) with advanced urothelial cancer progressing on or after a platinum containing regimen (NCT02033993).

2018 · Srikala S. Sridhar, Normand Blais, et al. · Journal of Clinical Oncology · 7

Unusual Carfilzomib Toxicity: Three Cases of Drug-induced Thrombotic Microangiopathy (TMA) after Treatment with High-dose weekly Carfilzomib, Cyclophosphamide, and Dexamethasone (wCCD)

2019 · Bethany Monteith, Chritopher Venner, et al. · Clinical Lymphoma Myeloma & Leukemia · 6

A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia

2021 · Matthew C. Cheung, Nicole Mittmann, et al. · Clinical Lymphoma Myeloma & Leukemia · 5

Overall and Progression Free Survival from the Mcrn-003/Myx.1 Trial: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma

2019 · Christopher P Venner, Richard Leblanc, et al. · Blood · 4

MCRN¯003/MYX·1: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma after 1-3 Prior Therapies

2018 · Christopher P. Venner, Richard Leblanc, et al. · Blood · 3

Inhibition of Phosphatidylinositol 3-kinase (pi3k) Signalling Leads to Resistance to Chemotherapeutic Agents in Human Cancer Cells

2008 · Gail T. McDonald · QSpace (Queen's University Library) · 2

A Prospective Economic Analysis of Canadian Cancer Trials Group Clc.2/Alliance A041202: A Randomized Phase III Comparison of Bendamustine-Rituximab Versus Ibrutinib-Based Regimens in Untreated Older Patients with Chronic Lymphocytic Leukemia

2020 · Matthew C. Cheung, Nicole Mittmann, et al. · Blood · 1

A multicenter randomized phase II trial comparing nab-paclitaxel to paclitaxel in patients with advanced urothelial cancer progressing on or after a platinum containing regimen: NCIC Clinical Trials Group BL 12 (NCT02033993).

2015 · Srikala S. Sridhar, Normand Blais, et al. · Journal of Clinical Oncology · 1

PA-315 MY.13: A Canadian-Led Non-Inferiority Phase III Trial in Progress Integrating Equity Principles in Transplant-Ineligible (TIE) Newly-Diagnosed (ND) Multiple Myeloma (MM)

2026 · Maria F. Comelles, Hira Mian, et al. · Clinical Lymphoma Myeloma & Leukemia

Correlation between phase 2 clinical trial design and subsequent phase 3 outcome.

2014 · Annette E. Hay, Jose Gerard Monzon, et al. · Journal of Clinical Oncology

Works count: 15

Citation count: 294

H-index: 6

I10-index: 5